This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD.

The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.

Key Inclusion Criteria of the master protocol:

• Able and willing to sign the informed consent (IC)
• Patients with a diagnosis of AD and onset of disease for at least 1 year
• Moderate to severe AD

Key Exclusion Criteria of the master protocol:

• Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
• Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
• Participant with any other active inflammatory skin disease
• Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
• Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)

Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements

Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com